Record Information |
---|
Version | 1.0 |
---|
Creation Date | 2016-05-26 07:09:46 UTC |
---|
Update Date | 2016-11-09 01:21:25 UTC |
---|
Accession Number | CHEM036024 |
---|
Identification |
---|
Common Name | Mesterolone |
---|
Class | Small Molecule |
---|
Description | Mesterolone is a synthetic anabolic-androgenic steroid (AAS) and derivative of dihydrotestosterone (DHT). It is inactivated by 3α-hydroxysteroid dehydrogenase in skeleta muscules so it is considered a weak androgen. It is not a substrate for aromatase so it is not converted into estrogen. Mesterolone demonstrated to have minimal effect on sperm counts and levels of FSH or LH [A27177, A27178]. Experiments of mesterolone serving as a potential treatment of depression are still undergoing. |
---|
Contaminant Sources | - FooDB Chemicals
- STOFF IDENT Compounds
|
---|
Contaminant Type | Not Available |
---|
Chemical Structure | |
---|
Synonyms | Value | Source |
---|
Proviron | MeSH | Vistimon | MeSH | SH-723Mesterolone | ChEMBL, HMDB | (1a,5a,17b)-17-Hydroxy-1-methyl-androstan-3-one | HMDB | 17b-Hydroxy-1a-methyl-5a-androstan-3-one | HMDB | 1a-Methyl-17b-hydroxy-5a-androstan-3-one | HMDB | 1a-Methyl-5a-androstan-17b-ol-3-one | HMDB | 1a-Methyl-5a-dihydrotestosterone | HMDB | Androviron | HMDB | Mesteranum | HMDB | Mestoranum | HMDB | Provirone 25 | HMDB | SH 723 | HMDB | Testiwop | HMDB | Jenapharm brand OF mesterolone | MeSH, HMDB | Schering brand OF mesterolone | MeSH, HMDB | Mesterolone jenapharm brand | MeSH, HMDB | Mesterolone schering brand | MeSH, HMDB |
|
---|
Chemical Formula | C20H32O2 |
---|
Average Molecular Mass | 304.467 g/mol |
---|
Monoisotopic Mass | 304.240 g/mol |
---|
CAS Registry Number | 1424-00-6 |
---|
IUPAC Name | (1S,2S,3S,7S,10R,11S,14S,15S)-14-hydroxy-2,3,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-5-one |
---|
Traditional Name | proviron |
---|
SMILES | [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)C[C@H](C)[C@]12C |
---|
InChI Identifier | InChI=1S/C20H32O2/c1-12-10-14(21)11-13-4-5-15-16-6-7-18(22)19(16,2)9-8-17(15)20(12,13)3/h12-13,15-18,22H,4-11H2,1-3H3/t12-,13-,15-,16-,17-,18-,19-,20-/m0/s1 |
---|
InChI Key | UXYRZJKIQKRJCF-TZPFWLJSSA-N |
---|
Chemical Taxonomy |
---|
Description | belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Steroids and steroid derivatives |
---|
Sub Class | Androstane steroids |
---|
Direct Parent | Androgens and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Androgen-skeleton
- 3-oxosteroid
- 3-oxo-5-alpha-steroid
- 17-hydroxysteroid
- Oxosteroid
- Hydroxysteroid
- Cyclic alcohol
- Cyclic ketone
- Secondary alcohol
- Ketone
- Organic oxygen compound
- Organooxygen compound
- Hydrocarbon derivative
- Carbonyl group
- Organic oxide
- Alcohol
- Aliphatic homopolycyclic compound
|
---|
Molecular Framework | Aliphatic homopolycyclic compounds |
---|
External Descriptors | |
---|
Biological Properties |
---|
Status | Detected and Not Quantified |
---|
Origin | Not Available |
---|
Cellular Locations | Not Available |
---|
Biofluid Locations | Not Available |
---|
Tissue Locations | Not Available |
---|
Pathways | Not Available |
---|
Applications | Not Available |
---|
Biological Roles | Not Available |
---|
Chemical Roles | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Appearance | Not Available |
---|
Experimental Properties | Property | Value |
---|
Melting Point | Not Available | Boiling Point | Not Available | Solubility | Not Available |
|
---|
Predicted Properties | |
---|
Spectra |
---|
Spectra | Spectrum Type | Description | Splash Key | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | splash10-03g1-0290000000-6711f2fd4cedd8b8ebe9 | Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (1 TMS) - 70eV, Positive | splash10-03dj-2029000000-d49394c5377c1d882480 | Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | Not Available | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-052r-0195000000-44dcd42d89336ba3b750 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-052r-0291000000-412b4cbbe59f184a654f | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-052o-1790000000-09c00b6e9a55d7df2300 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-0udi-0029000000-e48e22f298cdef547931 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-0udi-0059000000-231f9da9a32e84b9b604 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-007c-3090000000-69a7d162e0bb3918d70b | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-0udi-0009000000-f9d10b76ade80bd401ad | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-0udi-0009000000-f9d10b76ade80bd401ad | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-0udj-0094000000-7cb92f7f18ba37686418 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-0a4i-0079000000-2860312a6cf9370e1957 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-0a4r-0960000000-9c3e64e51c3a7c290a00 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-0a4i-3910000000-a9991caf02a89a982090 | Spectrum |
|
---|
Toxicity Profile |
---|
Route of Exposure | Not Available |
---|
Mechanism of Toxicity | Not Available |
---|
Metabolism | Not Available |
---|
Toxicity Values | Not Available |
---|
Lethal Dose | Not Available |
---|
Carcinogenicity (IARC Classification) | Not Available |
---|
Uses/Sources | Not Available |
---|
Minimum Risk Level | Not Available |
---|
Health Effects | Not Available |
---|
Symptoms | Not Available |
---|
Treatment | Not Available |
---|
Concentrations |
---|
| Not Available |
---|
External Links |
---|
DrugBank ID | DB13587 |
---|
HMDB ID | HMDB0006036 |
---|
FooDB ID | FDB023812 |
---|
Phenol Explorer ID | Not Available |
---|
KNApSAcK ID | Not Available |
---|
BiGG ID | Not Available |
---|
BioCyc ID | Not Available |
---|
METLIN ID | Not Available |
---|
PDB ID | Not Available |
---|
Wikipedia Link | Mesterolone |
---|
Chemspider ID | 14296 |
---|
ChEBI ID | 529213 |
---|
PubChem Compound ID | 15020 |
---|
Kegg Compound ID | D04947 |
---|
YMDB ID | Not Available |
---|
ECMDB ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
MSDS | Not Available |
---|
General References | 1. Petry R, Rausch-Stroomann JG, Hienz HA, Senge T, Mauss J: Androgen treatment without inhibiting effect on hypophysis and male gonads. Biochemical and morphological studies after treatment with Mesterolone. Acta Endocrinol (Copenh). 1968 Nov;59(3):497-507. | 2. Ho EN, Leung DK, Leung GN, Wan TS, Wong HN, Xu X, Yeung JH: Metabolic studies of mesterolone in horses. Anal Chim Acta. 2007 Jul 16;596(1):149-55. Epub 2007 Jun 3. | 3. Vandekerckhove P, Lilford R, Vail A, Hughes E: Androgens versus placebo or no treatment for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev. 2000;(2):CD000150. | 4. Vandekerckhove P, Lilford R, Vail A, Hughes E: WITHDRAWN: Androgens versus placebo or no treatment for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev. 2007 Jul 18;(4):CD000150. | 5. Schell H: [Objective assessment of therapeutic hair growth--methods, possibilities and problems]. Z Hautkr. 1990 Dec;65(12):1080-4. | 6. Cooper AJ: Short-term treatment in sexual dysfunction: a review. Compr Psychiatry. 1981 Mar-Apr;22(2):206-17. | 7. Itil TM: The discovery of antidepressant drugs by computer-analyzed human cerebral bio-electrical potentials (CEEG). Prog Neurobiol. 1983;20(3-4):185-249. | 8. Schill WB, Michalopoulos M: Treatment of male fertility disturbances. Current concepts. Drugs. 1984 Sep;28(3):263-80. | 9. Mbizvo MT: Functional motion changes during sperm transit to the site of fertilization and in-vitro applications: a review. Int J Androl. 1995 Jun;18 Suppl 1:1-6. | 10. Herrmann WM, Beach RC: Psychotropic effects of androgens: a review of clinical observations and new human experimental findings. Pharmakopsychiatr Neuropsychopharmakol. 1976 Sep;9(5):205-19. |
|
---|